/
EWTX
$43.18-$0.38 (-0.87%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$4.7B
109M shares
52-week range
$13.50 – $48.40
85% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Change+$28.02
Edgewise Therapeutics, Inc. Common Stock
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.
www.edgewisetx.com- Employees
- 127
- IPO / List date
- Mar 26, 2021
- HQ
- BOULDER, CO
Held by traders on TradeandTell
No one on the platform currently holds EWTX.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2024-09-30 | 27,465 | $733.0K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded EWTX yet.
